The European Journal of Health Economics

2002 - 2026

Current editor(s): J.-M.G.v.d. Schulenburg

From:
Springer
Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ)
Contact information at EDIRC.
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().

Access Statistics for this journal.
Is something missing from the series or not right? See the RePEc data check for the archive and series.

Volume 27, issue 4, 2026

Message from the New Editor-in-Chief pp. 779-780

Arndt Reichert

Are there differences in health state preferences between urban and rural respondents? a comparison using time trade-off and discrete choice experiment pp. 781-790

Shitong Xie, Jing Wu and Feng Xie

Far more than a shot in the arm: Vaccines and consumer spending pp. 791-800

Serhan Cevik

Educational gradient in physiological risk factors in a workplace: a decomposition analysis of biomarkers pp. 801-819

Toshiaki Aizawa

Economic burden and cost drivers of interstitial lung disease: a systematic review pp. 821-842

Siow Yeh Chiew, Mustapha Mohammed and Siew Chin Ong

Quality of life utility-Core 10 dimensions (QLU-C10D) scores based on cancer patients’ health preferences are more sensitive than those based on general public’s health preferences pp. 843-855

Yiyin Cao, Haofei Li, Xu Jin, Madeleine T. King, Richard Norman, Ling Jie Cheng, Hongjuan Yu, Weidong Huang and Nan Luo

Mapping of the EORTC QLQ-LC43 to EQ-5D-5 L index in patients with lung cancer: comparison of traditional regression models with machine learning technique pp. 857-868

Longlin Jiang, Yan Miao, Hong Zhou, Lin Peng, Yongtao Han, Xi Luo, Qiuling Shi, Xuefeng Leng and Qing Yang

Long-term effectiveness and cost-effectiveness of testing for alemtuzumab antidrug antibodies to guide treatment in multiple sclerosis: a modelling study pp. 869-879

Timothy Jamieson, Florian Tomini, Sharmilee Gnanapavan and Borislava Mihaylova

Change in healthcare resource use and associated costs of patients with metastatic lung cancer between 2013 and 2021: an observational study from the French national health data system pp. 881-891

Christos Chouaid, Clarisse Marchal, Marion Apert, Lionel Bensimon, Valérie Guimard, Mélanie Née, Manon Belhassen, Gérard de Pouvourville and Jean-Yves Blay

Eliciting discounting model and direction at the individual level with time trade-off follow-up questions pp. 893-903

Michał Jakubczyk

Is next generation sequencing for the diagnosis of rare diseases worth its cost? A user-based approach to valuation pp. 905-914

Karen V. MacDonald, Sebastian Heidenreich, Nicolas Krucien, Kym M. Boycott, Francois P. Bernier, Mandy Ryan and Deborah A. Marshall

Cost analysis of transthyretin amyloid cardiomyopathy in heart failure patients with preserved ejection fraction in Spain pp. 915-927

Pablo García-Pavía, José Manuel García-Pinilla, Javier Rejas-Gutierrez, Laura Bernal, Patricia Tarilonte and Carmen Peral

Multinational stakeholder engagement to inform future development and refinement of the EuroQol toddler and infant populations (EQ-TIPS) pp. 929-944

J. Verstraete, S. Schieskow, J. Jelsma, M. Herdman, B. M. Morrow, K. Dalziel and E. Bidgood

Volume 27, issue 3, 2026

Labor market entry prospects of people with visual impairments: evidence from administrative register data in the Netherlands pp. 509-526

Katharina Diehl, Eline Heppe, Melvin Vooren, Ilja Cornelisz and Chris van Klaveren

Estimating QALYs in adults with cerebral palsy: mapping the San Martin scale to the EQ-5D-5L for economic evaluation pp. 527-540

Diana Marcela Nova Díaz, Aritz Adin and Eduardo Sánchez-Iriso

Cost-utility analysis of a web-based interactive patient education platform: evidence from a randomized clinical trial for end-stage renal disease patients pp. 541-552

Modou Diop, Lionel Perrier, Baptiste Haon, Lise Rochaix, Luc Behaghel, Jean-Claude K. Dupont, Magali Morelle, Michelle Elias, Laure Esposito, Christophe Legendre, Hélène Longuet, Isabelle Durand-Zaleski and Evangéline Pillebout

Does chronic disease coverage for outpatient care affect healthcare utilization and expenditures in China? Evidence from an administrative claim dataset pp. 553-569

Wen He and Yanyao Li

Total costs of different lines of treatment in diffuse large B-cell lymphoma in Denmark – a real-world data analysis pp. 571-580

Christian Graves Beck, Martin Lucas Jørgensen, Maya Friis Kjaergaard, Søren Ramme Bro and Tove Holm-Larsen

Pembrolizumab vs. chemotherapy in the first-line setting of PD-L1 ≥ 50% metastatic non-small cell lung cancer: a real-world cost-effectiveness analysis pp. 581-590

Brandon Liu, Ambica Parmar, Jin Luo, Wei Fang Dai and Kelvin K. W. Chan

Does access to quality accreditation improve health? - Patient-level evidence from German cancer care pp. 591-607

Tim Brand and Katharina Blankart

United Kingdom value set for the functional assessment of cancer therapy eight dimension (FACT-8D) preference-based quality of life instrument pp. 609-622

R. Norman, R. Campbell, D. Rowen, R. Viney, D. J. Street, F. Müller, R. Mercieca-Bebber, A. S. Pickard, D. Cella, J. W. Shaw and M. T. King

Does opt-out legislation crowd out living organ donations? A cross-country study pp. 623-636

Stefan Felder and Richard Abbasi

Informing decisions in light of parameter uncertainty – an economic evaluation of the adjuvanted recombinant herpes zoster vaccine in Sweden pp. 637-649

Camilla Nystrand, Katarina Widgren, Shuang Hao, Emelie Heintz and Vibeke Sparring

TF-TAVI and SAVR post-procedural complications in Germany 2021/2022 – impact on healthcare resource consumption pp. 651-661

Alexander Maier, Alicja Zientara, Markus Jäckel, Jonathan Rilinger, Christian Weber, Vera Oettinger, Lukas A. Heger, Derek Hazard, Roman Gottardi, Martin Czerny, Dirk Westermann, Constantin von zur Mühlen and Klaus Kaier

Trends in the economic burden of mental disorders over twelve years: the Netherlands mental health survey and incidence study pp. 663-673

S.J. Korteling, M. ten Have, F.W. Thielen, S. van Dorsselaer, M. Tuithof, A.I. Luik and B.F.M. Wijnen

Comparing the measurement properties of the EQ-5D-Y-3L and EQ-5D-3L in a general population sample of adults pp. 675-689

Anna Nikl, Valentin Brodszky, Ákos Szabó and Fanni Rencz

Costs of productivity loss up to two years after ischaemic stroke pp. 691-698

Ilse Huijberts, Robert J. van Oostenbrugge, Wim H. van Zwam, Alida A. Postma and Florentina M.E. Pinckaers

Predicting brand share after LOE in chronic disease market using machine learning pp. 699-714

Seho Park and Kahyun Lee

Do EQ-5D-Y-3L value sets have common properties, and how do they compare to EQ-5D-5L value sets? pp. 715-729

Bram Roudijk, Tianxin Pan, Jan Abel Olsen and Nancy Devlin

Breaking the habit: a systematic review of the cost-effectiveness of non-pharmacological and combined interventions for smoking cessation in Europe pp. 731-755

Alexander Braun, Walter Hyll and Eva Krczal

Variation in patient-reported outcomes after total hip replacement across ten high-volume hospitals in Germany: results from a multicenter, prospective, longitudinal Cohort Study pp. 757-768

Martin Emmert, Cornelia Frömke, Cordula Drach, Laura Heppe, Susann Kiss, Christiane Patzelt, Anja Schindler, Oliver Schöffski, Jona Stahmeyer, Julia Weber and Uwe Sander

Child- versus adult-perspective composite time trade-off valuations for the EQ-5D-Y-3L: evidence from the Hungarian valuation study pp. 769-778

Stevanus Pangestu, Bram Roudijk, Fanni Rencz and Stefan A. Lipman

Volume 27, issue 2, 2026

Measuring hospital care resilience: a systematic literature review pp. 175-211

Marina Cavalieri, Stefania Fontana, Calogero Guccio, Domenico Lisi, Marco Ferdinando Martorana, Giacomo Pignataro and Domenica Romeo

Nexus among health expenditures, ICTs and sustainable economic growth: Insights from South Asian Nationals health and economic issues pp. 213-219

Linmin Chen, Aysha Zamir, Malik Shahzad Shabbir, Andrei Octavian Paraschivescu, Violeta Hazaparu, Florin Radu, Mohammad Jaradat, Iancu Dorin, Gabriela Fotache, Raul Adrian Lile, Ramona Lile, Rusu Corina-Maria and Bondac Georgiana Tatiana

Valuing health states for infants and toddlers: challenges and methodological considerations in EQ-TIPS preference elicitation pp. 221-233

Nancy Devlin, Bram Roudijk, Michael Herdman, Elly Stolk, Richard Norman, Simone Kreimeier and Janine Verstraete

Willingness to pay for measures to increase use of active school transport pp. 235-244

Kristina Ek, Anna-Karin Lindqvist, Ellen Gustavsson Niemi, Stina Rutberg and Nadja Sirviö

Health-related quality of life in patients with alcohol use disorder: comparing instruments and mapping from clinical measures to preference-based measures pp. 245-258

Eva Rodríguez-Míguez and Jacinto Mosquera

The value of health and well-being from a societal perspective: A willingness to pay experiment in the Netherlands pp. 259-276

Karen Trujillo Jara, Daphne C. Voormolen, Werner Brouwer and Job van Exel

Cost-effectiveness analysis of the covered endovascular reconstruction of the aortic bifurcation versus kissing stents and open surgical repair for the treatment of aorto-iliac occlusive disease pp. 277-287

Xavier G. L. V. Pouwels, Suzanne Holewijn, Daphne van der Veen, Mauricio Gonzalez-Urquijo, Michel M. P. J. Reijnen and Hendrik Koffijberg

Comparison of the psychometric performance of experimental EuroQol Toddler and Infant Populations Instrument (EQ-TIPS) and Pediatric Quality of Life Inventory™ (PedsQL) in young children pp. 289-304

Tianxin Pan, Li Huang, Vicky He, Janine Verstraete, Nancy Devlin, Mike Herdman and Kim Dalziel

Unravelling heterogeneity in efficiency measurements: a case study of public hospitals in Spain pp. 305-318

Marta Arbelo-Pérez, Violeta De Vera and Antonio Arbelo

Exploration of using constrained regression in Germany’s morbidity-based risk adjustment pp. 319-337

Florian Renker, Dennis Häckl and Amelie Wuppermann

Valuing health and wellbeing using discrete choice experiment: exploring feasibility, design effect and international preference similarity pp. 339-353

Haode Wang, Donna L. Rowen, Yuen Chen, Clara Mukuria, Deborah Street and Richard Norman

Nothing about us, without us? A reflection on and call for involving children in the process of valuing child health pp. 355-362

Ava Hoogenboom, Vivian Reckers-Droog, Stefan Lipman and Werner Brouwer

Economic evaluation of advanced practice physiotherapy models of care for upper extremity musculoskeletal disorders In Denmark: a registry-based cohort study pp. 363-372

Simon Lafrance, Cecilie Rud Budtz, Martin Byskov Kinnerup, François Desmeules, Jason Robert Guertin, Merete Nørgaard Madsen and David Høyrup Christiansen

Hesitancy and compulsory vaccination: are non-mandatory vaccines the victims? A study on Italian regions pp. 373-390

Luisa Loiacono, Riccardo Puglisi, Leonzio Rizzo and Riccardo Secomandi

PROM-based monitoring and alerts reduce post-surgery healthcare utilization of patients undergoing joint replacement: A secondary analysis of the PROMoting Quality RCT pp. 391-410

David Ehlig, Lukas Schöner, Alexander Geissler, Laura Wittich, Reinhard Busse and Justus Vogel

Comparing EQ-5D-5L and SF-6Dv2 utilities with QLU-C10D utilities in hematologic cancer patients pp. 411-421

Tiantian Zhang, Aixue Zhang, Jing Li, Fangyu Li, Peng Liu and Pei Wang

Healthcare costs associated with gender dysphoria in children, adolescents and young adults in germany: A prevalence-based analysis using statutory health insurance data pp. 423-433

Sophie Gottschalk, Claudia Konnopka, Katja Nettermann, Alicia Başoğlu, Ursula Marschall, Dirk Horenkamp-Sonntag, Angela Rölver, André Karch, Georg Romer and Hans-Helmut König

Translating the EORTC CAT core and the QLQ-C30 to the EQ-5D-5L in patients with metastatic breast cancer: A comparison of direct and indirect mapping algorithms pp. 435-451

Pimrapat Gebert, Anna Maria Hage, Felix Fischer, Christoph Paul Klapproth, Ulrike Grittner and Maria Margarete Karsten

Tough versus soft regulations to promote generic medications in Italy pp. 453-477

Aarushi Dhingra, Gianluca Fiorentini, Ayman Fouda and Naomi Moy

Price determinants and pricing policies concerning potentially innovative health technologies: a scoping review pp. 479-508

Nicolas S. H. Xander, Tom Belleman, Maximilian Salcher-Konrad, Anne Hendrickx, Jeffrey Chen, Anne-Sophie Klein Gebbink, Peter Schneider, Kate Morgan, Oliver Groene, Isabelle Durand-Zaleski, Frederick W. Thielen and Carin A. Uyl- de Groot

Volume 27, issue 1, 2026

Long-term costs associated with healthcare use of people with cancer in Scotland pp. 1-15

Kenny Haining, Elizabeth Lemmon, Peter Hall and Nazir I. Lone

Predicting EQ-5D-3L utility values from clinical data in a prospective cohort of kidney transplant recipients pp. 17-28

V. Bonnemains, Y. Foucher, P. Tessier, C. David, M. Giral and E. Dantan

Clinical equivalence and non-inferiority within health technology assessment pp. 29-45

Matthew Taylor, Joe Goldbacher, Charlotte Graham, James Mahon and Mike Chambers

Time preferences and COVID-19 vaccination uptake pp. 47-63

Arthur Attema, Marcello Antonini, Mesfin Genie, Aleksandra Torbica and Francesco Paolucci

Cost-effectiveness of Mavacamten for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy using a French healthcare perspective pp. 65-76

Francois-Emery Cotté, Michael Hurst, Sarah Akarkoub, Melissa Ho, Julien Vernon, Lou Chambry and Sandy Leproust

Cost-effectiveness of treatments for presymptomatic newborn patients with spinal muscular atrophy and two or three copies of the survival motor neuron 2 gene in Italy pp. 77-94

Ilaria Valentini, Gianni Ghetti, Marika Pane, Filippo Rumi, Eugenio Di Brino, Michele Basile, Gabriele Maria Pistillo and Matthias Bischof

Trends in physical and mental health needs across generations in Australia pp. 95-116

Sabrina Lenzen, Luke Connelly, William Whittaker and Stephen Birch

A model-based cost-effectiveness analysis of prescribing by dietitians and therapeutic radiographers in England pp. 117-133

Saeideh Babashahi, Nicola Carey, Karen Stenner, Kath Hart, Yogini Jani, Judith Edwards and Natalia Hounsome

Pharmacy cost groups for the German morbidity-based risk compensation scheme pp. 135-147

Christian J. A. Schindler, Benjamin Berndt and Dennis Häckl

Health economic outcomes and national economic impacts associated with Long COVID in England and Scotland pp. 149-166

Joseph Kwon, Joseph Mensah, Ruairidh Milne, Clare Rayner, Román Rocha Lawrence, Johannes De Kock, Manoj Sivan and Stavros Petrou

Critical issues with methods and results interpretation at validating the EQ-5D-5L and QLU-C10D utilities in gastric cancer patients pp. 167-169

Simone Seyringer and Eva Maria Gamper

Do we need a health technology assessment approach for non-inferiority specifically? A comment on: clinical equivalence and non-inferiority within health technology assessment by Taylor et al. (2025) pp. 171-172

Beryl Primrose Gladstone and Werner Vach

Cost-of-illness of myelodysplastic syndromes in Italy. A reply to Tse et al pp. 173-174

Carlo Lazzaro